Aventyn

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Aventyn sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 3 currently recruiting 3 completed upper quartile by trial count

Aventyn: 6 sponsored US clinical trials, 3 recruiting.

Aventyn sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Acute MI, with 2 trials.

Upper-quartile sponsor footprint

Aventyn sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Aventyn pipeline

3 recruiting of 6 indexed (50% open); 3 completed (50%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Acute MI (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aventyn: open-pipeline peers nationwide

Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Aventyn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1234567 0%20%40%60%80% Total trials Recruiting share Aventyn23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Aventyn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aventyn sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Aventyn page

6 registered trials is a research-attention snapshot, not an endorsement of Aventyn or any single study.

  • 3 of Aventyn's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute MI is the condition Aventyn studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute MI trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aventyn pipeline card: 6 registered trials from official public datasets.Report a data error.